Suppr超能文献

血浆胰岛素样生长因子I水平在抑郁和焦虑症中较高,但在使用抗抑郁药物的患者中较低。

Plasma insulin-like growth factor I levels are higher in depressive and anxiety disorders, but lower in antidepressant medication users.

作者信息

Bot Mariska, Milaneschi Yuri, Penninx Brenda W J H, Drent Madeleine L

机构信息

VU University Medical Center and GGZ inGeest, Department of Psychiatry, EMGO Institute for Health and Care Research, Amsterdam, The Netherlands.

VU University Medical Center and GGZ inGeest, Department of Psychiatry, EMGO Institute for Health and Care Research, Amsterdam, The Netherlands.

出版信息

Psychoneuroendocrinology. 2016 Jun;68:148-55. doi: 10.1016/j.psyneuen.2016.02.028. Epub 2016 Feb 27.

Abstract

It has been postulated that many peripheral and (neuro)biological systems are involved in psychiatric disorders such as depression. Some studies found associations of depression and antidepressant treatment with insulin-like growth factor 1 (IGF-I) - a pleiotropic hormone affecting neuronal growth, survival and plasticity - but evidence is mixed. We therefore studied whether depressive and anxiety disorders were associated with plasma IGF-I, and explored the role of antidepressant medication in this association in a large observational study. The sample consisted of 2714 participants enrolled in The Netherlands Study of Depression and Anxiety, classified as healthy controls (n=602), antidepressant users (76 remitted and 571 with current depressive and/or anxiety disorder(s), n=647), persons having remitted depressive and/or anxiety disorder(s) without antidepressant use (n=502), and persons having current depressive and/or anxiety disorder(s) without antidepressant use (n=963). Associations with IGF-I concentrations were studied and adjusted for socio-demographic, health, and lifestyle variables. Relative to healthy controls, antidepressant-free individuals with current disorders had significantly higher IGF-I levels (Cohen's d=0.08, p=0.006), whereas antidepressant-free individuals with remitted disorders had a trend towards higher IGF-I levels (d=0.06, p=0.09). Associations were evident for depressive and for anxiety disorders. In contrast, antidepressant users had significantly lower IGF-I levels compared to healthy controls (d=-0.08, p=0.028). Our findings suggests that antidepressant medication use modifies the association between depressive/anxiety disorders and plasma IGF-I. These results corroborate with findings of some previous small-scale case-control and intervention studies. The higher IGF-I levels related to depression and anxiety might point to a compensatory mechanism to counterbalance the impaired neurogenesis, although future studies are needed to support this hypothesis.

摘要

据推测,许多外周和(神经)生物学系统都与抑郁症等精神疾病有关。一些研究发现抑郁症及抗抑郁治疗与胰岛素样生长因子1(IGF-I)有关,胰岛素样生长因子1是一种影响神经元生长、存活和可塑性的多效性激素,但证据并不一致。因此,我们在一项大型观察性研究中,研究了抑郁和焦虑症是否与血浆IGF-I相关,并探讨了抗抑郁药物在这种关联中的作用。样本包括2714名参与荷兰抑郁与焦虑研究的参与者,分为健康对照组(n = 602)、抗抑郁药使用者(76名已缓解者和571名患有当前抑郁和/或焦虑症者,n = 647)、未使用抗抑郁药的已缓解抑郁和/或焦虑症患者(n = 502)以及未使用抗抑郁药的患有当前抑郁和/或焦虑症者(n = 963)。研究了与IGF-I浓度的关联,并对社会人口统计学、健康和生活方式变量进行了调整。与健康对照组相比,当前患有疾病且未使用抗抑郁药的个体的IGF-I水平显著更高(科恩d值 = 0.08,p = 0.006),而患有已缓解疾病且未使用抗抑郁药的个体的IGF-I水平有升高趋势(d = 0.06,p = 0.09)。抑郁和焦虑症的关联均很明显。相比之下,与健康对照组相比,抗抑郁药使用者的IGF-I水平显著更低(d = -0.08,p = 0.028)。我们的研究结果表明,使用抗抑郁药物会改变抑郁/焦虑症与血浆IGF-I之间的关联。这些结果与之前一些小规模病例对照和干预研究的结果一致。与抑郁和焦虑相关的较高IGF-I水平可能指向一种补偿机制,以抵消受损的神经发生,不过需要未来的研究来支持这一假设。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验